X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Torrent Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs TEVA PHARMA (Israel) - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 TORRENT PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
TEVA PHARMA
Dec-13
TORRENT PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5503,010-   
Low Rs1,1442,615-   
Sales per share (Unadj.) Rs354.71,727.6-  
Earnings per share (Unadj.) Rs40.1107.9-  
Cash flow per share (Unadj.) Rs64.2247.6-  
Dividends per share (Unadj.) Rs14.0094.48-  
Dividend yield (eoy) %1.03.4 30.9%  
Book value per share (Unadj.) Rs273.11,919.1-  
Shares outstanding (eoy) m169.22848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.81.6 233.2%   
Avg P/E ratio x33.626.1 128.9%  
P/CF ratio (eoy) x21.011.4 184.6%  
Price / Book Value ratio x4.91.5 336.4%  
Dividend payout %34.987.5 39.9%   
Avg Mkt Cap Rs m227,8972,385,153 9.6%   
No. of employees `00014.744.9 32.7%   
Total wages/salary Rs m11,3530-   
Avg. sales/employee Rs Th4,083.032,596.4 12.5%   
Avg. wages/employee Rs Th772.30-   
Avg. net profit/employee Rs Th461.32,036.3 22.7%   
INCOME DATA
Net Sales Rs m60,0211,465,046 4.1%  
Other income Rs m2,9880-   
Total revenues Rs m63,0091,465,046 4.3%   
Gross profit Rs m13,493401,204 3.4%  
Depreciation Rs m4,086118,421 3.5%   
Interest Rs m3,08528,776 10.7%   
Profit before tax Rs m9,310254,007 3.7%   
Minority Interest Rs m01,154 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-166,741 0.0%   
Tax Rs m2,529-3,101 -81.5%   
Profit after tax Rs m6,78191,520 7.4%  
Gross profit margin %22.527.4 82.1%  
Effective tax rate %27.2-1.2 -2,224.7%   
Net profit margin %11.36.2 180.9%  
BALANCE SHEET DATA
Current assets Rs m52,623989,486 5.3%   
Current liabilities Rs m52,022862,916 6.0%   
Net working cap to sales %1.08.6 11.6%  
Current ratio x1.01.1 88.2%  
Inventory Days Days12091 131.7%  
Debtors Days Days7696 79.5%  
Net fixed assets Rs m85,016478,516 17.8%   
Share capital Rs m8463,606 23.5%   
"Free" reserves Rs m45,3760-   
Net worth Rs m46,2221,627,388 2.8%   
Long term debt Rs m41,115749,110 5.5%   
Total assets Rs m142,4323,348,099 4.3%  
Interest coverage x4.09.8 40.9%   
Debt to equity ratio x0.90.5 193.2%  
Sales to assets ratio x0.40.4 96.3%   
Return on assets %6.93.6 192.8%  
Return on equity %14.75.6 260.9%  
Return on capital %14.24.9 287.8%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,9800-   
CASH FLOW
From Operations Rs m8,942233,452 3.8%  
From Investments Rs m-47,070-82,722 56.9%  
From Financial Activity Rs m34,174-280,042 -12.2%  
Net Cashflow Rs m-3,655-129,311 2.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 72.12 Rs / USD

Compare TORRENT PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare TORRENT PHARMA With: DR. REDDYS LAB  LUPIN LTD  GLENMARK PHARMA  PANACEA BIOTECH  TTK HEALTHCARE  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views On News

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Nov 15, 2018 03:35 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS